Benign dermal neurilemmoma

Summary

Benign dermal neurilemmoma (MONDO:0004134) is a disease. A subtype of skin neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	benign dermal neurilemmoma
Mondo ID	MONDO:0004134
DOID	DOID:7181
NCIT	C5569
UMLS	C5686033
MedGen	1810230
Is cancer (heuristic)	no

Also known as: benign dermal schwannoma · benign neurilemmoma of skin · benign neurilemmoma of the skin · benign schwannoma of skin · benign schwannoma of the skin · benign skin neurilemmoma · benign skin schwannoma

Disease family

This is a subtype of skin neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › skin neoplasm › benign dermal neurilemmoma

Related subtypes (16): dermoid cyst of skin, eyelid neoplasm, epidermal appendage tumor, dermis tumor, skin cancer, actinic keratosis, familial Dupuytren contracture, schwannomatosis, familial multiple discoid fibromas, Maffucci syndrome, hemangiopericytoma of skin, benign neoplasm of skin, melanocytic skin neoplasm, epithelial skin neoplasm, calcifying epithelial odontogenic tumor, familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.